Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
about
Intestinal microbiota as modulators of the immune system and neuroimmune system: impact on the host health and homeostasisReciprocal cross-talk between Nod2 and TAK1 signaling pathwaysExpanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn diseasePsychological stress in IBD: new insights into pathogenic and therapeutic implications.Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn's disease.Behavioral interventions may prolong remission in patients with inflammatory bowel disease.Gene transfer approaches for the treatment of inflammatory bowel disease.Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trialDeficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitisNitric oxide inhibitable isoforms of adenylate cyclase mediate epithelial secretory dysfunction following exposure to ionising radiation.Role of the CARD15 gene in the pathogenesis of Crohn disease: phenotypic classification and prognostic implications.Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases.Events at the host-microbial interface of the gastrointestinal tract. I. Adaptation to a microbial world: role of epithelial bactericidal/permeability-increasing protein.Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organPlasma long noncoding RNA expression profile identified by microarray in patients with Crohn's disease.Taking Crohn's disease personallyHelicobacter pylori and Crohn's disease: a retrospective single-center study from ChinaCARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure.Helicobacter pylori infection and inflammatory bowel disease: is there a link?Immunoregulation of Inflammatory and Inhibitory Cytokines by Vitamin D3 in Patients with Inflammatory Bowel Diseases.Celastrol: A Spectrum of Treatment Opportunities in Chronic DiseasesSynthesis of biologically active biotinylated muramyl dipeptides.Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.Endogenous antigen presenting cell-derived IL-10 inhibits T lymphocyte responses to commensal enteric bacteria.CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn's disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2.Hyperresponsiveness of the Mucosal Barrier in Crohnʼs Disease Is Not Tumor Necrosis Factor-Dependent
P2860
Q21284481-D59ABF46-BE36-489F-8A60-C34A695DF98FQ24336336-710A3486-E81B-469E-853C-13A51BFE77C6Q30434096-E9A0E702-5CDD-4318-AC52-A8B94E66012EQ30493180-85DED37F-3FC6-4332-8473-A781F6CBDA56Q34243614-476F110B-825E-408A-A2FC-D31F2E20973CQ34590491-4618C2E3-F327-4363-B47C-52711DB130E9Q35122162-35A68149-3F8B-405D-B9A1-02257C7547BCQ35594296-F59E1B1C-A541-4F12-A2A6-E7121BFD3101Q35596664-6AC6825F-9CFF-429B-8A20-DB40D1D56360Q35598243-A1791B62-42F9-49D2-88A4-9CC6EC679959Q35611913-7E4A8856-5B50-44DB-AD29-6AACF7B4C4AFQ36022832-A45B8728-41E0-4EE1-9AA1-D03A959B2E03Q36069861-5E4B24A6-5DF7-476A-AA3E-DC2D4AABCC4CQ36886503-EF59312A-5367-4E08-BE3B-36A922403F6DQ36909245-E72A206C-4BD8-40E8-99AB-1788F4759962Q36919248-BFDD468B-5735-45AE-BF9D-9F23B02E5DC4Q37050515-8400BC52-BF2C-471D-9BF7-1D4B35A087FDQ37362309-8478A9DE-F820-4444-A3D6-5C65036A64B8Q38219027-70208E13-1E2D-4ABE-962A-341B25F46EF8Q39195198-6F1F6211-6A92-4EAA-BB24-9FAABABF59EAQ39406168-98E2A6B6-C596-44A6-B884-65F6359664ECQ39658629-DBAEF05B-90E9-451A-8063-47DF0361DEB9Q41174004-66352B7A-6225-4389-9C86-CDE35F55159CQ41963779-37521F69-2D90-4BCA-97DB-C90CABC50F42Q49118975-E6A6E1A5-D347-4832-AC13-F97981F9B6A0Q52608505-2462F9EF-839F-4605-A6C1-36029BE033DFQ57265441-C584153E-6B27-4EE4-B319-0C1DB69FEF80
P2860
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@ast
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@en
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@nl
type
label
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@ast
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@en
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@nl
prefLabel
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@ast
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@en
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@nl
P1476
Genes, microbes, and T cells--new therapeutic targets in Crohn's disease.
@en
P2093
Charles O Elson
P304
P356
10.1056/NEJM200202213460812
P407
P577
2002-02-01T00:00:00Z